Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults

scientific article published in July 2006

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1089/AID.2006.22.678
P698PubMed publication ID16831092
P5875ResearchGate publication ID6954669

P50authorConnie CelumQ42571941
Guido FerrariQ56481169
David C. MontefioriQ63302725
Nina D. RussellQ109927619
Elizabeth NoonanQ109934089
Kent J. WeinholdQ109935303
P2093author name stringJ M Smith
M J Mulligan
J Kahn
H L Robinson
R R Amara
NIH/NIAID/DAIDS HIV Vaccine Trials Network
P433issue7
P921main subjectvaccineQ134808
vector-borne diseaseQ2083837
P304page(s)678-683
P577publication date2006-07-01
P1433published inAIDS Research and Human RetrovirusesQ4651880
P1476titleExcellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults
P478volume22

Reverse relations

cites work (P2860)
Q46171221Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses
Q55432126Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.
Q33614476Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine
Q42410705Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques
Q37329415Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.
Q36528901Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
Q42554027Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
Q37103923Current progress of DNA vaccine studies in humans
Q34492802DNA/MVA Vaccines for HIV/AIDS
Q35857215Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors
Q28972526Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
Q36498186Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".
Q45031334Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation
Q38877415Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans
Q37773283Maternal immunization to modulate the development of allergic response and pathogen infections.
Q36748019Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration
Q33645528Novel directions in HIV-1 vaccines revealed from clinical trials
Q38586079Nucleic acid vaccination strategies against infectious diseases.
Q30378897Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
Q33527383Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine
Q34772727Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
Q30379200Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).
Q39862726Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge
Q91890041Rectal Microbiome Composition Correlates with Humoral Immunity to HIV-1 in Vaccinated Rhesus Macaques
Q36668517Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
Q45398885Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults
Q27016078Synthetic DNA vaccine strategies against persistent viral infections
Q24602593Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

Search more.